Drug
DB 1311 Bnt324
DB 1311 Bnt324: highest development phase Phase 2, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| DB-1311/BNT324 NCT06953089 | Phase 2 | Solid Tumors |
Latest
No recent events.
Follow DB 1311 Bnt324 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.